Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin

Molecular Pharmacology

Volumn 56, Issue 2, 1999, Pages 390-395

  Lin, Xinjian ^a   Howell, Stephen B ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; PACLITAXEL; TOPOTECAN;

ARTICLE; BASE MISPAIRING; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; DNA REPAIR; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0032803291     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.2.390     Document Type: Article

References (36)

1. Aquilina G, Hess P, Fiumicino S, Ceccotti S and Bignami M (1994) A mutator phenotype characterizes one of two complementation groups in human cells tolerant to methylation damage. Cancer Res 55:2569-2575.
2. Benedetti P, Fiorani P, Capuani L and Wang JC (1993) Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res 53:4343-4348.
3. Bhattacharyya NP, Skandalis A, Ganesh A, Groden J and Meuth M (1994) Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci USA 91:319-6323.
4. Cariello NF, Swenberg JA and Skopek TR (1992) In vitro mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltransferase gene. Cancer Res 52:2866-2873.
5. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 56:4881-4886.
6. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L and Sikic BI (1996) Resistance mechanism in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 58:1091-1097.
7. Eastman A (1986) Reevaluation of interaction of cis-dichloro(ethylenediainine)platinum (II) with DNA. Biochemistry 25:3912-3915.
8. Fishel R and Kolodner RD (1995) Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5:382-395.
9. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M and Kolodner R (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038.
10. Fink D, Nebel S, Aebi S, Nehme A and Howell SB (1997) Lose of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. Intl J Oncol 11:539-542.
11. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen R and Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886.
12. Glaab WE and Tindall K (1997) Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 18:1-8.
13. Griffin S, Branch P, Xu YZ and Karran P (1994) DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: Implications for tolerance to DNA methylation damage. Biochemistry 33:4787-4793.
14. Hemminki A, Peltomaki P, Mecklin JP, Jarvinen H, Salovaara R, Nystrom-Lahti M, de la Chapelle A and Aaltonen LA (1994) Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet 8:405-410.
15. Hess P, Aquilina G, Dogliotti E and Bignami M (1994) Spontaneous mutations at aprt locus in a mammalian cell line defective in mismatch recognition. Somat Cell Mol Genet 20:409-421.
16. Hoffmann JS, Pillaire MJ, Garcia-Estefania D, Lapalus S and Villani G (1996) In vitro bypass replication of the cisplatin-d (GpG) lesion by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase is highly mutagenic. J Biol Chem 271:15386-15392.
17. Hoffmann JS, Pillaire MJ, Lesca C, Burnouf D, Fuchs RP, Defais M and Villani G (1997) Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates. Proc Natl Acad Sci USA 93:13766-13769.
18. Huang J, Papadopoulos N, McKinley AJ, Farrington SM, Curtis LJ, Wyllie AH, Zheng S, Willson JK, Markowitz SD, Morin P, Kinzler KW, Vogelstein B and Dunlop MG (1996) APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci USA 93:9049-9054.
19. Johnson NP, Hoeschele JD, Rahn RO, O'Neill JP and Hsie AW (1980) Mutagenicity, cytotoxicity, and DNA binding of platinum (IIII)-chloroammines in Chinese hamster ovary cells. Cancer Res 40:1463-1468.
20. Kat A, Thilly WG, Fang W, Longley MJ, Li G and Modrich P (1995) An alkylationtoleration, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90:6424-6428.
21. Koi M, Umar A, Chaudan DP, Cherian SP, Carethers JM, Kunkel TA and Boland CR (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitroguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54:4308-4312.
22. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomäki P, Sistonen, P, Aaltonen LA and Nyström-Lahti M (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-1225.
23. Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, Papadopoulos N, Peltomäki P, de la Chapelle A and Hamilton SR (1995) Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 9:48-58.
24. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW and Vogelstein B (1995) Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science (Wash DC) 268:1336-1338.
25. Owens JK, Shewach DS, Ullman B and Mitchell BS (1992) Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutation with the deoxycytidine kinase gene. Cancer Res 52:2389-2393.
26. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM and Adams MD (1994) Mutation of a mutL homolog in hereditary colon cancer. Science (Wash DC) 263:1625-1629.
27. + tumor cells. Cell 75:1227-1236.
28. Rampino N, Yamamoto H, Inonv Y, Li Y, Sawai H, Reed JC and Perucho M (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (Wash DC) 275:967-969.
29. Turnbull NC, Popescu JA, Dipaolo JA and Myhr BC (1979) Cisplatinum (IIII) diammine dichloride causes mutation, transformation, and sister-chromatid exchanges in cultured mammalian cells. Mutat Res 66:267-275.
30. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, Boland CR, Barrett JC and Kunkel TA (1997) Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 57:3948-3955.
31. Umar A and Kunkel TA (1996) DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Eur J Biochem 238:297-307.
32. Wiencke JK, Cervenka J and Paulus H (1979) Mutagenic activity of anticancer agent cis-dichlorodiammine platinum-IIII. Mutat Res 68:69-77.
33. Wooster R, Cleton-Jansen AM, Collins N, Mangion J, Cornelis RS, Cooper CS, Gusterson BA, Ponder BA, Von Deimling A and Wiestler OD (1994) Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet 6:152-156.
34. Yamada M, O'Regan E, Brown R and Karran P (1997) Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res 25:491-495.
35. Yarema KJ, Lippard SJ and Essigmann JM (1995) Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). Nucleic Acids Res 23:4066-4072.
36. Yarema KJ, Wilson JM, Lippard SJ and Essigmann JM (1994) Effects of DNA adduct structure and distribution on the mutagenicity and genotoxidty of two platinum anticancer drugs. J Mol Biol 236:1034-1048.